Article
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
All News
Article
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!
Dr. John Cush
Tweet
Upadacitinib is a Double Edged Vascular Sword in GCA
Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25.
https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D
Dr. John Cush
Tweet
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE
Dr. Sheila Reyes reports on the scientific session presentation of the #ACR25 treatment guidelines for SLE
https://t.co/Bh1fSFf8ju https://t.co/OH8h9GDeMf
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Nouf Al hemmadi
Tweet
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g
@synovialjoints discussed TriNetX data base looking at GLP-1 medications effect on MACE in PsA patients.
@RheumNow
#ACR25
Nouf Al hemmadi
Tweet
NEPTUNUS: Ianalumab in Sjogren's https://t.co/K9Xm51Kb5X
Finally good news in Sjogrens disease.
@RheumNow
#ACR25
Md Yuzaiful Md Yusof
Tweet
#ACR25 Please find my blog on update and progress of clinical trials in #Sjogren #SjD @RheumNow
https://t.co/u8pxZ5FeBX https://t.co/KAnRo3Zqnz
David Liew
Tweet
Andrew Yee @andrew02114 of @MGHCancerCenter details out how quickly the CAR-T paradigm changed in myeloma/lymphoma - from newsworthy to routine. Now that much more about CAR-T has been worked out, will adoption be quicker in autoimmune disease? #ACR25 BCRC pre-meeting @RheumNow https://t.co/oNuPXCwWQ9
Janet Pope
Tweet
What to use in future for active #Sjogren's #SjD
B cell depletion, signal attenuation
Ianalumab 2+ phase3 RCTs
Telitacept +RCT
Nipocalimab FcRn +Ph2
Dazodalibep CD40L +Ph2
+RCTs
HCQ+Lef
Rituximab
?BTKi
#ACR25 @ACRheum @RheumNow
abst#LB24, LB11
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush
Tweet
Next Generation T-Cell Engager: The Future
Dr. Alfred Kim reviews abstract 0001 presented at #ACR25.
https://t.co/vmZYfmKCm8 https://t.co/PkLOs9lZ8l
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.
Dr. John Cush
Tweet
CAR-T Cell Therapies Show Promise for Autoimmune Disease
Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc
Janet Pope
Tweet
Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis?
Early data n=6 treated w low dose (3 per arm), ongoing and doses will escalate
Improvemt in #clinical #disease #activity
less inflammation on #synovial #biopsies 3 pts
#LB23 #ACR25 @RheumNow @ACRheum https://t.co/PkhsvztVjx
Janet Pope
Tweet
#PD1 Ab looks good and safe in active RA
Rosnilimab, a Selective and Potent Depleter of Pathogenic T
Many failed several Rx already
No safety signals compared to another PD1i
Proof of benefit in biospecimens too!
abst#LB19 #ACR25 @RheumNow @ACRheum
#ACRBest https://t.co/TmEOCfuHZU
Akhil Sood MD, MS
Tweet
TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation):
🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol
🔹similar adverse events reported (14.6% vs 16.4%)
@RheumNow #ACR25 https://t.co/Yuql3O9C8X
Dr. John Cush
Tweet
Older Adults Underrepresented in RCTs
Drs. Jiha Lee and Sebastian Sattui discuss abstract 1072, "Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review," presented at #ACR25
https://t.co/uzSPH5RbjM https://t.co/94Vw6qUOIL
Md Yuzaiful Md Yusof
Tweet
#ACR25 Abstr#2695 Inguinal lymph node biopsies pre- and post-OBI, RTX, BLIN & CD19 CAR-T showed complete tissue depletion with CAR-T. B-cells reduced but often incomplete with protein-based depleters; OBI being the best. Still don’t agree with “immune reset” @RheumNow #ACRBest https://t.co/Sq7m9sXlLP
Akhil Sood MD, MS
Tweet
Abstract 2697: Compared to MMF, tacrolimus showed
- similar SRR by week 96 (58.5% vs. 69.2%, OR 0.62; 95% CI 0.29-1.29)
- similar time to renal AE/deaths (HR 0.70; 95% CI 0.37-1.35)
- serious AEs less frequent (12.3% vs. 30.8%)
@RheumNow #ACR25 https://t.co/o3LtgOp7St
